Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 663-676
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663
Table 3 Treatment-emergent and drug-related adverse events
Adverse event | Participants, n (%) | |||
Grade I | Grade II | Grade III | Grade IV | |
Hematological | ||||
Decreased platelet count | 14 (21.2) | 8 (12.1) | 3 (4.5) | 0 (0) |
Decreased neutrophil count | 15 (22.7) | 11 (16.7) | 2 (3.0) | 0 (0) |
Non-hematological | ||||
Elevated alanine | 30 (45.5) | 8 (12.1) | 4 (6.1) | 4 (6.1) |
Elevated serum bilirubin | 20 (30.3) | 26 (39.4) | 5 (7.6) | 0 (0) |
Nausea and vomiting | 32 (48.5) | 8 (12.1) | 0 (0) | 0 (0) |
Pain | 29 (43.9) | 11 (16.7) | 0 (0) | 0 (0) |
Fever | 4 (6.1) | 2 (3.0) | 0 (0) | 0 (0) |
Diarrhea | 10 (15.2) | 6 (9.1) | 0 (0) | 0 (0) |
Hand-foot skin reaction | 7 (10.6) | 16 (24.2) | 4 (6.1) | 0 (0) |
Neurotoxicity | 18 (27.3) | 7 (10.6) | 0 (0) | 0 (0) |
- Citation: Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
- URL: https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.663